Pharmaceutical - Asia-Pacific, North America


Current filters:

Asia-PacificNorth America

Popular Filters

1 to 25 of 35 results

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade


Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

US global share of biomedical research spending declines, as Asia gains


The USA’s global share of biomedical research spending fell from 51% in 2007 to 45% in 2012, while…

Asia-PacificChinaFinancialNorth AmericaPharmaceuticalRegulationResearchUSA

Review of key drivers of migraine market growth through 2022


Use of Allergan’s Botox (botulinum toxin type A) for the prophylactic treatment of chronic migraine…

AllerganAsia-PacificBotoxCoLucid PharmaceuticalsEuropelasmiditanLevadexMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

Eisai’s R&D organization undergoes “transformation”

Eisai’s R&D organization undergoes “transformation”


Japanese drugmaker Eisai's president and chief executive, Haruo Naito, says that the company's R&D organization,…

Asia-PacificEisaiEuropeManagementNorth AmericaPharmaceuticalResearchUSA

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan


There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Incidence of post-herpetic neuralgia set for steady increase by 2022


Due to the growth of the elderly population worldwide, the number of post-herpetic neuralgia (PHN) incident…

Asia-PacificEuropeMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

Eisai enters agreement to develop treatments for neglected tropical diseases

Eisai enters agreement to develop treatments for neglected tropical diseases


Eisai (TYO: 4523) has entered into a global agreement with the Broad Institute to jointly discover and…

Asia-PacificEisaiNorth AmericaPharmaceuticalResearchTropical diseases

Trajenta studies prove efficacy in broad range of diabetes patients

Trajenta studies prove efficacy in broad range of diabetes patients


Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and…

Asia-PacificBoehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalResearchTrajentaUSA

Through 2022, growth in the neuropathic pain drug market will be constrained by generics


The loss of US and European market exclusivity of three sales-leading neuropathic pain (NP) agents -…

Asia-PacificCymbaltaEli LillyEndo PharmaceuticalsEuropeLidodermLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

Sagent Pharma debuts Carboplatin Injection

Sagent Pharma debuts Carboplatin Injection


US specialty drugmaker Sagent Pharmaceuticals has announced the launch of Carboplatin Injection, an antineoplastic…

Asia-PacificCarboplatinMarkets & MarketingNorth AmericaOncologyPharmaceuticalProductionSagent Pharmaceuticals

Takeda partners with newly-formed Tri-1 TDI

Takeda partners with newly-formed Tri-1 TDI


The USA’s Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical…

Asia-PacificFinancialNorth AmericaPharmaceuticalResearchTakeda Pharmaceuticals

Prostate cancer market set to grow 50% by 2021: report


The increasing number of sufferers and the uptake of new drugs will see the prostate cancer market grow…

Asia-PacificAstellas PharmaEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalXtandiZytiga

AstraZeneca to fork out $815 million for rights to anemia drug candidate


In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

Sales of psoriasis drugs to be worth $7.4 billion by 2020


The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

FDA approves Eisai's Aciphex Sprinkle for GERD in children; Inovelon OKed in Japan


Japanese drug major Eisai (TYO: 4523) says that the US Food and Drug Administration has approved Aciphex…

AciphexAsia-PacificEisaiGastro-intestinalsInovelonNeurologicalNorth AmericaPharmaceuticalRegulation

Call for strong Trans-Pacific intellectual property framework from PhRMA


The Pharmaceutical Research and Manufacturers of America (PhRMA) this week called on nations participating…

Asia-PacificBiotechnologyNorth AmericaPatentsPharmaceuticalSouth America

Canada's Pharmascience sets up JV with Korea Kolmar; buys Rivex


Privately-held Canadian drugmaker Pharmascience and Korea Kolmar Holdings, based in Seoul, South Korea,…

Asia-PacificBiotechnologyGenericsHelix BioPharmaKorea KolmarMergers & AcquisitionsNeurologicalNorth AmericaPharmaceuticalPharmascienceRivex Pharma

$210 financing for Intarcia's for diabetes product; and China's Innovent raises $25 million


California, USA-based Intarcia Therapeutics last week announced the simultaneous completion of two financings…

Asia-PacificBiotechnologyFinancialInnovent BiologicsIntarcia TherapeuticsNorth AmericaPharmaceuticalProductionResearch

AstraZeneca gains rights to sell Ironwood's IBS drug in China


Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into an agreement with the USA's Ironwood…

Asia-PacificAstraZenecaGastro-intestinalsIronwood PharmaceuticalsLicensinglinaclotideMarkets & MarketingNexiumNorth AmericaPharmaceutical

1 to 25 of 35 results

Back to top